Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Koshiya Tapped as Global Head of Oncology: Sumitomo Dainippon
March 23, 2017
- Japan Begins Using PD-L1 Expression Biomarker for Immune Checkpoint Inhibitors, but Challenges Linger
March 22, 2017
- US Biotech X-Chem Inks Collaboration Deals with Astellas, Ono
March 22, 2017
- Praluent Shows Consistent Efficacy, Safety in Diabetic and Non-Diabetic Patients: Japanese Subanalysis
March 22, 2017
- Ribomic Links Up with Astellas for Research on Development of Aptamer Therapy
March 22, 2017
- Hitachi Chemical to Buy US Cell Therapy Contract Manufacturer, Japan-Bound Operations Slated for FY2018
March 21, 2017
- Daiichi Sankyo, NIBIOHN Hook Up in Cancer Immunology with Mitsubishi Funding
March 17, 2017
- Novartis Vows Continued Reforms despite Not-Guilty Diovan Ruling
March 17, 2017
- Court Finds Data Manipulation, but Not False Advertising: Diovan Case
March 17, 2017
- Lilly to Continue Investment in Alzheimer’s after Solanezumab Setback: Japan Development Chief
March 16, 2017
- Lilly’s Japan Sales Keep Momentum in 2016 with 3.1% Rise
March 16, 2017
- Novartis, Ex-Employee Found Not Guilty in Diovan Case
March 16, 2017
- Takeda Revving Up Partnership Initiatives
March 15, 2017
- Maruho Gets Global Rights to Toray’s RORγt Inhibitor
March 15, 2017
- Takeda Biotech JV to Focus on 8 Projects for Now, Eyes IPO: CEO Okumura
March 15, 2017
- Kissei, Maruishi Join Hands on Opioid Receptor Agonist
March 14, 2017
- INCJ, Takeda, Medipal to Form Biotech Venture
March 14, 2017
- Daiichi Sankyo Taps Heptares for Pain Med Discovery Research
March 14, 2017
- Daiichi Sankyo Launches Large-Scale Observational Study for Cancer VTE
March 14, 2017
- Toyama Chemical, Towa Settle Patent Suit over Ozex Pediatric Drug
March 14, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…